Natural products with translocase I inhibitory activity, as new lead compounds against tuberculosis;Produtos naturais com atividade inibitória da translocase I, uma promissora classe de compostos contra tuberculose

Boletin Latinoamericano y del Caribe de Plantas Medicinales y Aromaticas

Volumn 9, Issue 1, 2010, Pages 1-12

  De Souza, Marcus Vinícius Nora ^a   Facchinetti, Victor ^a   Cardinot, Danielle ^a   Gomes, Claudia Regina Brandão ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Streptomyces; Translocase I; Tuberculosis

Indexed keywords

A 500359A; A 500359E; CALANOLIDE A; CAPRAZAMICINE DERIVATIVE; CAPRAZOL; CAPURAMICINA; CAPURAMICINE DERIVATIVE; CARRIER PROTEIN; ENZYME INHIBITOR; ETHAMBUTOL; ISONIAZID; LIPOSIDOMICINA I; LIPOSIDOMICINA II; LIPOSIDOMICINA III; LIPOSIDOMICINA IV; LIPOSIDOMICINE DERIVATIVE; MURAIMICINE DERIVATIVE; MUREIDOMICINE DERIVATIVE; NAPSAMICINE DERIVATIVE; NATURAL PRODUCT; PACIDAMICINE DERIVATIVE; PALMITOILCAPRAZOL; PEPTIDOGLYCAN; PYRAZINAMIDE; RIFAMPICIN; RS 124922; TRANSLOCASE I; TUBERCULOSTATIC AGENT; TUNICAMICINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BACTERIUM ISOLATE; BIOSYNTHESIS; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; HUMAN; LUNG TUBERCULOSIS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; REVIEW; STREPTOMYCES; STRUCTURE ACTIVITY RELATION; TUBERCULOSIS CONTROL;

HUMAN IMMUNODEFICIENCY VIRUS; MYCOBACTERIUM TUBERCULOSIS; STREPTOMYCES;

EID: 76749171748     PISSN: None     EISSN: 07177917     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Boojamra CG, Lemoine RC, Lee JC, Léger R, Stein KA, Vernier NG, Magon A, Lomovskaya O, Martin PK, Chamberland S, Lee MD, Hecker S J, Lee VJ. 2001. Stereochemical elucidation and total synthesis of dihydropacidamycins D, a semisynthetic pacidamicyn. J. Am. Chem. Soc. 123(5): 870-874.
2. Boojamra CG, Lemoine RC, Blais J, Vernier NG, Stein K A, Magon A, Chamberland S, Hecker S J, Lee V J. 2003 Synthetic dihydropacidamycin antibiotics: A modified spectrum of activity for the pacidamycin class. Bioorg. Med. Chem. Lett. 13: 3305-3309.
3. Boyle DS, Donachie WD. 1998. mraY is an essential gene for cell growth in Echeriachia Coli. J. Bacteriol. 180(23) 6429-6432.
4. Bugg TDH, Walsh, CT. 1992. Intracellular steps of bacterial cell wall peptidoglycan biosynthesis: Enzymology, antibiotics and antibiotic resistance. Nat. Prod. Rep. 9: 199-215.
5. Centers For Disease Control And Prevention. Extensively Drug-Resistant Tuberculosis (XDR TB). http://www.cdc.gov/tb/xdrtb/ (consulted June 29, 2009)
6. Chatterjee S, Nadkarni SR, Vijayakumar EKS, Patel MV, GANGULI B N. 1994. J. Antibiot. 47(5): 595-598.
7. Chen R H, Buko AM, Whittern DN, Mcalpine JB. 1989. Pacidamycins, a novel series of antibiotics with anti-pseudomonas aeruginosa activity. II. Isolation and structural elucidation. J. Antibiot. 42(4): 512-520.
8. Chumkaew P, Karalai C, Ponglimanont C, Chantrapromma K. 2003. Antimycobacterial Activity of Phorbol Esters from the Fruits of Sapium indicum J. Nat. Prod. 66: 540-543.
9. De Souza MVN, Vasconcelos TRA. 2005a. Fármacos no combate à tuberculose: passado, presente e futuro. Quím. Nova. 28(4): 678-682.
10. De Souza MV. 2005b. Plants and fungal products with activity against tuberculosis. ScientificWorldJournal. 5:609-28.
11. De Souza MVN. 2006a. Tuberculose em pacientes HIV-positivos: um grave problema de saúde pública mundial. Rev. Bras. Farm. 87: 42-44.
12. De Souza MVN. 2006b. Current status and future prospects for new therapies for pulmonary tuberculosis. Curr. Opin. Pulm. Med. 12(3): 167-171.
13. De Souza MVN. 2006d. Marine natural products against tuberculosis. ScientificWorldJournal. 6:847-861.
14. De Souza MVN, Ferreira ML, Pinheiro AC, Saraiva MF, Almeida MV, Valle MS. 2008. Synthesis and biological aspects of mycolic acids: an important target against mycobacterium tuberculosis. ScientificWorldJournal. 8: 720-751.
15. De Souza MVN. 2009. Promising candidates in clinical trials against multidrug-resistant tuberculosis (MDR-TB) based on natural products. Fitoterapia. Edizione Farmaceutica. 80: 453-460.
16. Dini C, Collette P, Drochon N, Guillot JC, Lemoine G, Mauvais P, Aszodi J. 2000. Synthesis of the nucleoside moiety of liposidomycins: elucidation of the pharmacophore of this family of MraY inhibitors. Bioorg. Med. Chem. Lett. 10: 1839-1843.
17. Dini C, Drochon N, Feteanu S, Guillot JC, Peixoto C, Aszodi J. 2001a. Synthesis of analogues of the O-β-D-ribofuranosyl nucleoside moiety of liposidomicyns. Part 1: contribution of the amino group and the uracil moiety upon the inhibition of MraY. Bioorg. Med. Chem. Lett. 11: 529-531.
18. Dini C, Drochon N, Guillot JC, Mauvais P, Walter P, Aszodi J. 2001b. Synthesis of analogues of the O-β-D-ribofuranosyl nucleoside moiety of liposidomicyns. Part 2: role of the hydroxyl groups upon the inhibition of MraY. Bioorg. Med. Chem. Lett. 11: 533-536.
19. Fernandes P B, Swanson R N, Hardy D J, Hanson C W, Coen L, Rasmussen R R, Chen R H. 1989. Pacidamycins, a novel series of antibiotics with anti-Pseudomonas aeruginosa activity. III. Microbiologic profile. J. antibiotic. XLII (4). 521-526.
20. Heijenoort, JV .2001. Recent advances in the formation of bacterial peptidoglycan monomer unit. Nat. Prod. Rep. 18:503-519.
21. Heydanek MG, Struve WG, Neuhaus FC. 1969. Initial state in peptidoglycan synthesis. III. Kinetics and uncoupling of phospho-N-acetylmuramylpentapeptide translocase (uridine 5′-phosphate). Biochem. 63(8): 1214-1221.
22. Hirano S, Ichikawa S, Matsuda A. 2008a. Synthesis of caprazamycin analogues and their structure activity relationship for antibacterial activity. J. Org. Chem. 73(2): 569-577.
23. Hirano S, Ichikawa S, Matsuda A. 2008b. Structure-activity relationship of truncated analogs of caprazamycins as potential anti-tuberculosis agents. Bioorg. Med. Chem. 16: 5123-5133.
24. Hotoda H, Furukawa M, Daigo M, Murayama K, Kaneko M, Muramatsu Y, Ishii M M, Miyakoshi S, Takatsu T, Inukai M, Kakuta M, Abe T, Harasaki T, Fukuoka T, Utsui Y, Ohya S. 2003a. Synthesis and antimycobacterial activity of capuramycin analogues. Part 1: substitutions of the azepan-2-one moiety of capuramycin. Bioorg. Med. Chem. Lett. 13: 2829-2832.
25. Hotoda H, Daigo M, Furukawa M, Murayama K, Hasegawa C A, Kaneko M, Muramatsu Y, Ishii M M, Miyakoshi S, Takatsu T, Inukai M, Kakuta M, Abe T, Fukuoka T, Utsui Y, Ohya S. 2003b. Synthesis and antimycobacterial activity of capuamycin analogues. Part 2: acylated derivatives of capuramycin-related compounds. Bioorg. Med. Chem. Lett. 13: 2833-2836.
26. Ichikawa S. 2008. Nucleoside chemistry based on nucleoside natural products synthesis. Chem Pharm. Bull. 56(8): 1059-1072.
27. Ichikawa S, Matsuda A. 2007. Nucleoside natural products and related analogs with potential therapeutic properties as antibacterial and antiviral agents. Expert Opin. Ther. Pat. 17(5): 487-498.
28. Igarashi M, Takahashi Y, Shitara T, Nakamura H, Naganawa H, Miyake T, Akamatsu Y. 2005. Caprazamycins, novel lipo-nucleoside antibiotics, from Streptomices sp. J. Antibiot. 58(5): 327-337.
29. Inukai M, Isono F, Takatsuki A. 1993. Selective inhibition of the bacterial translocasereaction in peptidoglycan synthesis by mureidomycins. Antimicrob. Agents Chemother.37(5): 980-983.
30. Isono K, Uramoto M, Kusakabe H, Kimura K I, Igasi K, Nelson C C, McCloskey JA. 1985. Liposidomycins: novel nucleoside antibiotics which inhibit bacterial peptidoglycan synthesis. J. Antibiotics. 38(11): 1617-1621.
31. Isono F, Kodoma K, Inukai M. 1992. Susceptibily of Pseudomonas species to the novel antibiotics mureidomycins. Antimicob. Agents Chemother. 36(5): 1024-1027.
32. Kanokmedhakul S, Kanokmedhakul K, Kanarsa T, Buayairaksa. 2005. New Bioactive Clerodane Diterpenoids from the Bark of Casearia grewiifolia. J. Nat. Prod. 68: 183-188.
33. Kanokmedhakul, S, Kanokmedhakul K, Nambuddee K, Kongsaeree P. 2004. New Bioactive Prenylflavonoids and Dibenzocycloheptene Derivative from Roots of Dendrolobium lanceolatum. J. Nat. Prod. 67: 968-972.
34. Kimura KI, Iked Y, Kagami S, Yoshihama M, Suzuki K, Osada H, Isono K. 1998. Selective inhibition of the bacterial peptidoglycan biosynthesis by the new types of liposidomycins. J. Antibiotics. 51(12): 1099-1104.
35. Kimura K, Bugg TDH. 2003. Recent advances in antimicrobial nucleoside antibiotics targeting cell wall biosynthesis. Nat. Prod. Rep. 20: 252-273.
36. Koga T, Fukuoka T, Doi N, Harasaki T, Inoue H, Hotoda H, Kakuta M, Muramatsu Y, Yamamura N, Hoshi M, Hirota T. 2004. Activity of capuramycin analogues against Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium intracellulare in vitro and in vivo. J. Antimicrob. Chemother. 54: 755-760.
37. Lin Y, Li Z, Francisco GD, Mcdonald LA, Davis RA, Singn G, Yang Y, Mansour T S. 2002. Muraymicyns, novel peptidoglycan biosynthesis inhibitors: semisynthesis and SAR of their derivatives. 12(17): 2341-2344.
38. McDonald LA, Barbieri LR, Carter GT, Lenoy E, Lotvin J, Petersen PJ, Siegel MM, Singh G, Williamson R T. 2002. Structures of muraymicyns. novel peptidoglycan biosynthesis inhibitors. J. Am. Chem. Soc. 124 (35): 10260-10261.
39. Nikaido H, Saier JR MH. 1994. Transport proteins in bacteria: common themes in their design. Science. 258(5084): 936-942.
40. Sayed KAE, Hamann MT, EL-Rahman HA A, Zaghloul AM. 1998. New Pyrrole Alkaloids from Solanum sodomaeum. J. Nat. Prod. 61: 848-850.
41. Struve WG, Sinha RK, Neuhaus FC. 1966. On the initial stage in peptidoglycan synthesis. Phospho-N-acetylmuramylpentapeptide tranlocase (uridine monophosphate). Biochem. 5(1): 82-93.
42. World Health Organization. Tuberculosis (TB). http://www.who.int/tb/en/ (consulted June 16, 2009)
43. Xu ZQ, Barrow WW, Suling WJ, Westbrook L, Barrow E, Lin Y M, Flavin M .T. 2004. Anti-HIV natural product (+)-calanolide A is active against both drug-susceptible and drug-resistant strains of Mycobacterium tuberculosis. Bioorg. Med. Chem. 12: 1199-1207.